Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.85 |
| ▸ | IKZF3 | Q9UKT9 | 18/20 | 0.85 |
| ▸ | TNF | P01375 | 3/20 | 0.85 |
| ▸ | IL1B | P01584 | 3/20 | 0.85 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.85 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.85 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2252489 | 1.00 | CRBN (0.85) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL26318062 | 0.95 | CRBN (0.91) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL26321494 | 0.95 | CRBN (0.91) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL29260002 | 0.94 | CRBN (0.84) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL29260006 | 0.94 | CRBN (0.84) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2252296 | 0.93 | CRBN (0.91) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2252158 | 0.93 | CRBN (0.85) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2249491 | 0.92 | CRBN (0.84) | CRBNIKZF3TNFIL1BDDB1 | |
| SCHEMBL2249858 | 0.92 | CRBN (1.00) | CRBNIKZF3TNFIL1BDDB1 | |
| Iberdomide SCHEMBL2246002 | 0.92 | CRBN (1.00) | CRBNIKZF3TNFIL1BDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4289838-A2 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | Celgene Corporation (US) | 2023-12-13 | — | — | EP | disclosed |